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Abstract
Background: Polymorphonuclear neutrophils (PMN) constitute an essential cellular component
of innate host defense against microbial invasion and exhibit a wide array of responses both to
particulate and soluble stimuli. As the cells recruited earliest during acute inflammation, PMN
respond rapidly and release a variety of potent cytotoxic agents within minutes of exposure to
microbes or their products. PMN rely on the redistribution of functionally important proteins,
from intracellular compartments to the plasma membrane and phagosome, as the means by which
to respond quickly. To determine the range of membrane proteins available for rapid recruitment
during PMN activation, we analyzed the proteins in subcellular fractions enriched for plasma
membrane and secretory vesicles recovered from the light membrane fraction of resting PMN after
Percoll gradient centrifugation and free-flow electrophoresis purification using mass spectrometry-
based proteomics methods.
Results: To identify the proteins light membrane fractions enriched for plasma membrane vesicles
and secretory vesicles, we employed a proteomic approach, first using MALDI-TOF (peptide mass
fingerprinting) and then by HPLC-MS/MS using a 3D ion trap mass spectrometer to analyze the two
vesicle populations from resting PMN. We identified several proteins that are functionally
important but had not previously been recovered in PMN secretory vesicles. Two such proteins,
5-lipoxygenase-activating protein (FLAP) and dysferlin were further validated by immunoblot
analysis.
Conclusion: Our data demonstrate the broad array of proteins present in secretory vesicles that
provides the PMN with the capacity for remarkable and rapid reorganization of its plasma
membrane after exposure to proinflammatory agents or stimuli.
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Background
Human polymorphonuclear leukocytes (neutrophils or
PMN) are essential for optimal host defense against
invading microorganisms and employ both oxygen-
dependent and -independent agents in concert to kill and
degrade ingested microbe [1]. The cell biology of PMN is
especially tailored to mediate the rapid and efficient
responses that characterize the innate immune system
early in inflammation. Stimulation of PMN triggers sev-
eral concurrent events that together mount a potent cyto-
toxic response to invading microbes or other noxious
agents [2].
The initiation of phagocytosis stimulates the assembly
and activation of the NADPH oxidase (reviewed in [3]),
resulting in the PMN undergoing a burst of oxygen con-
sumption and generation of reactive oxygen species. The
NADPH oxidase is a multicomponent enzyme complex
that is unassembled and inactive in the resting PMN, with
essential components segregated in distinct cellular com-
partments (i.e. membrane vs. cytoplasm) in the unstimu-
lated cell. When PMN are stimulated, the cytosolic
elements translocate to the plasma or phagosomal mem-
brane where they associate with the membrane-bound fla-
vocytochrome b558 to form a functional oxidase complex.
Simultaneously the intracellular granules fuse with the
phagosomal membrane, thereby releasing their contents
into the same compartment as that in which the reactive
oxygen species are being generated [4-6]. The granule con-
tents include proteolytic enzymes such as elastase [7] pro-
teins that are directly toxic to target microbes such as the
defensins [8,9] or bactericidal permeability increasing
protein [10], and proteins that convert H2O2 into more
potent antimicrobial species [11]. Reactive oxygen spe-
cies, antimicrobial proteins, and hydrolytic enzymes not
only act independently but also cooperate synergistically
to create an environment within the phagosome that is
extremely inhospitable to the ingested microbe. Both oxi-
dase assembly and degranulation represent agonist-
dependent redistribution of prefabricated biological ele-
ments, a strategy of cellular response that is especially tai-
lored to the physiologic responsibilities of PMN within
the context of innate immunity and distinctly different
from one dependent on transcriptional control of the pro-
duction of reactive molecules [12].
Recent interest has focused on identification of the vari-
ous types of granules in PMN and their sequential mobi-
lization during activation. In addition to the distinct
granule populations, PMN contain secretory vesicles, a
unique and easily mobilizable compartment that co-sedi-
ments with plasma membrane in the light membrane
fraction of resting PMN [13]. Whereas the lumen of secre-
tory vesicles houses plasma proteins such as human
serum albumin, the membranes of this intracellular com-
partment contain a variety of functionally important
membrane proteins [reviewed in [14]]. During exposure
to proinflammatory stimuli, the secretory vesicles readily
fuse with the plasma membrane, thereby integrating its
resident membrane proteins with those constitutively
present at the PMN surface [14]. In this way the fusion of
secretory vesicles with the plasma membrane transforms
the resting PMN to a cell more suited to deliver cytotoxic
agents against invading microbes or other threatening
noxious agents [15,16].
The purpose of the present study is to employ proteomic
analysis of plasma membrane and secretory vesicles from
resting human PMN in order to define the repertoire of
functionally important membrane proteins available in
secretory vesicles for rapid recruitment to the plasma
membrane during PMN activation.
Results
Resolution of plasma membrane-enriched fractions from 
resting PMN
The light membrane fraction recovered from a two-step
Percoll density gradient separation of cavitated resting
PMN [13], the γ fraction, is enriched for plasma mem-
brane vesicles (PMV) but also contains secretory vesicles
(SV), a labile intracellular compartment whose mem-
branes contain several functionally important proteins
[17]. In light of the lability of SV and the facility with
which they fuse with the plasma membrane, it was essen-
tial to be confident that PMN used for study were truly at
rest. In the absence of endotoxin contamination, PMN
isolated from heparinized venous blood using sequential
dextran sedimentation and differential density centrifuga-
tion on Hypaque-Ficoll are neither primed nor stimu-
lated: they do not consume oxygen, indicating that the
NADPH oxidase is neither assembled nor active, and their
intracellular compartments remain intact [1]. For our
studies, we routinely screen the status of NADPH oxidase
activity, using superoxide dismutase-inhibitable reduc-
tion of ferricytochrome C to quantitate oxidant produc-
tion [18]. Routinely, PMN isolated by sequential dextran
sedimentation and differential density centrifugation on
Hypaque-Ficoll generate 1.01 ± 0.21 nmoles superoxide
anion/106 PMN/10 min (n = 9), whereas PMN stimulated
with 100 ng/ml of phorbol myristate acetate produce
78.47 ± 2.48 nmoles superoxide anion/106 PMN/10 min
(n = 9). Using the absence of oxidase activity as a criterion,
PMN used in these studies were at rest. Another feature of
resting PMN is the presence of 85% of the flavocyto-
chrome b558 (a heterodimer of gp91phox and p22phox and
the membrane component of the phagocyte NADPH oxi-
dase) in the specific granules [19]. To assess the distribu-
tion of flavocytochrome b558 in PMN used in our studies,
we immunoblotted an equal number of cell equivalents
of specific granules, PMV, and SV, the subcellular com-Proteome Science 2007, 5:12 http://www.proteomesci.com/content/5/1/12
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partments in which gp91phox is expressed [17]. Consistent
with previous reports, the majority of gp91phox  was
detected in specific granules (~80%), with PMV and SV
expressing ~20% of the remaining total (see Figure A1,
additional file 1). Taken together, the absence of oxidase
activity and the predominantly intracellular location of
flavocytochrome b558 demonstrate that the PMN used for
study were judged to be in the resting state.
The yield of light membranes retrieved from resting PMN
was reproducible, 0.90 ± 0.12 μg protein/106 cell equiva-
lents (CE) (n = 19). To identify the protein components of
secretory vesicles that would be newly available in the
plasma membrane after their fusion at the cell surface, we
resolved plasma membrane vesicles from secretory vesi-
cles in the membranes of resting PMN using free-flow
electrophoresis (FFE).
The secretory vesicles were distinguished from the plasma
membrane-derived vesicles by the presence of latent alka-
line phosphatase activity in the former, detected only after
their solubilization in T×100 (Figure 1). Whereas there
were two peaks of alkaline phosphatase activity recovered
from fractions after FFE, only one peak (fractions 12–20)
in resting PMN demonstrated latent activity (Figure 1).
The activity of the second peak (fractions 22–28) was
unchanged by T×100 treatment, consistent with these
fractions representing plasma membrane.
In order to minimize potential cross-contamination
between the two peaks, we pooled only the centermost
fractions of each of the two peaks, sacrificing yield for
purity. Using this more restricted collection of vesicles
from FFE, we obtained 0.10 ± 0.04 μg protein/106 CE and
0.14 ± 0.02 μg protein/106 CE for PMV and SV, respec-
tively (n = 19). Selected fractions from the two peaks were
pooled and the component proteins separated by SDS-
PAGE and stained with Sypro Ruby (Figure 2) for subse-
quent excision and analysis. Based on densitometer scan-
ning of both gel lanes, the total protein loaded from the
SV-enriched fraction was ~2-fold higher than that in the
PMV-enriched material.
Evidence for other light organelles in PMV- and SV-
enriched fractions
One would anticipate that the light membrane fraction of
resting PMN might include not only the PMV and SV, but
also membranes from other intracellular organelles with
similar low density. Although mature PMN are terminally
differentiated and exhibit limited proteins synthesis
under resting conditions [1], proteomic analyses of PMN
granules [20] and of PMN phagosomes [21] have reported
the recovery of proteins selectively expressed in ER, Golgi,
and mitochondria. However, there are no published data
that directly assess the presence of ER, mitochondria, or
Golgi in SV or PMV preparations derived from FFE of rest-
ing human PMN. To address this issue, we immunoblot-
ted equal numbers of cell equivalents of plasma PMV and
SV isolated by FFE of light membranes recovered from
resting PMN, and probed the fractions with antibodies
against calreticulin and calnexin (both molecular chaper-
ones residing in the ER), porin and cytochrome c (both
markers of mitochondria), and golgin 97 (marker for
Golgi) (Figure 3). As anticipated, the aforementioned
organelles co-sedimented with SV and with PM. Whereas
marker proteins for ER and mitochondria indicated rela-
tively more of these organelles in SV-enriched fractions,
an observation that is consistent with the mass spectro-
metric identification of mitochondrial and ER proteins
mentioned above, Golgi membranes co-sedimented with
PMV. We interpret the recovery of ER, mitochondrial, and
Golgi proteins in these fractions as evidence for co-sedi-
mentation of these organelles with PMV or SV, rather than
the bona fide expression of the marker proteins in PMV or
SV.
Composition of plasma membrane and secretory vesicle 
enriched fractions from PMN
To survey the most abundant proteins of plasma mem-
brane vesicles and secretory vesicles, we employed a pro-
teomic approach, first using immunochemistry, and then
Separation of plasma membrane vesicles and secretory vesi- cles from resting PMN Figure 1
Separation of plasma membrane vesicles and secre-
tory vesicles from resting PMN. Isolated resting PMN 
were disrupted by N2 cavitation and fractionated using a two-
step discontinuous gradient of Percoll. The γ-band containing 
the light membranes was recovered, treated with neuramini-
dase, and subjected to free-flow electrophoresis to resolve 
plasma membranes vesicles from secretory vesicles. Frac-
tions (96) were collected and assayed spectrophotometri-
cally for alkaline phosphatase activity in the absence (❍) and 
presence () of Triton X-100. Data are expressed as units of 
absorbance at 405 nm. Latent alkaline phosphatase activity 
indicates the presence of secretory vesicles.
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mass spectrometry (MALDI-TOF and HPLC-MS/MS) to
analyze the two vesicle populations from resting PMNs
after separation by 1D gel electrophoresis. Due to the
complexity of these mixtures, even after 1D gel separation,
MALDI-TOF peptide mass fingerprinting of the 27 gel
slices from each of the two preparations identified only a
few of the most abundant proteins: integrin alpha-M and
matrix metalloproteinase-9 in the secretory vesicle prepa-
ration, and moesin and beta-actin in the plasma mem-
brane fraction (data not shown). To obtain a more in-
depth coverage of the proteins in these two preparations,
the same trypsin-digested gel slices where subjected to
HPLC-MS/MS analysis. In this latter case, 43 and 37
unique proteins could be identified in the vesicle and
plasma membrane fractions, respectively (see additional
file 2, for Table A1).
Many proteins were recovered from both compartments.
For example, lyn and flotillin-1, markers of detergent-
resistant membranes or lipid rafts [22-24], were equally
distributed in plasma membrane vesicles and secretory
vesicles, based on Western blot analysis (Figure 4A). More
comprehensive analysis by HPLC-MS/MS likewise dem-
onstrated that the two compartments shared many of the
same proteins or protein classes, most notably those that
participate in adhesion, cytoskeletal events, and signal
transduction (Table 1 and additional file 3 for Table A2,).
In many of these cases, these proteins have been previ-
ously identified in vesicle compartments, such as the beta
integrins, CD13, CD45, flavocytochrome b558, and Rabs.
Although these mass spectrometric data sets were not
quantitative, one can use spectral counts as a rough indi-
cator of relative protein abundances [25]. It should be
Immunochemical analysis of plasma membrane vesicle- and  secretory vesicle-enriched fractions for other cell organelles Figure 3
Immunochemical analysis of plasma membrane vesi-
cle- and secretory vesicle-enriched fractions for 
other cell organelles. An equal number of cell equivalents 
of plasma membrane vesicles (PMV), and secretory vesicles 
SV, were separated by SDS-PAGE, electroblotted, and 
probed with antibodies against calreticulin and calnexin (both 
molecular chaperones residing in the ER), golgin 97 (marker 
for Golgi), porin and cytochrome c (both markers of mito-
chondria).
cytochrome c
calreticulin
porin
calnexin
PMV SV
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Proteins in fractions enriched for plasma membrane vesicles  or secretory vesicles from resting PMN Figure 2
Proteins in fractions enriched for plasma membrane 
vesicles or secretory vesicles from resting PMN. 
Secretory vesicles (a) and Plasma membrane vesicles (b) 
recovered by free-flow electrophoresis of isolated γ fraction 
from resting PMN were separated by PAGE on 4–20% SDS 
gradient gel and visualized by SYPRO ruby staining. The 
bands (indicated by numbers) from top to bottom in each 
lane were excised from the gel with the help of 1.5 mm band 
picker and processed with an automatic in-gel digester robot, 
ProGest as described in Materials and Methods. The num-
bers assigned to the bands in the gel correspond to the pro-
teins listed in Table A1 (Additional file 2).Proteome Science 2007, 5:12 http://www.proteomesci.com/content/5/1/12
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noted, however, that the total spectral counts obtained for
all proteins in the enriched SV preparation was ~2.6 times
higher than that obtained from the PMV preparation, con-
sistent with the densitometry estimation of a 2-fold differ-
ence in total protein loaded onto each gel, and therefore
should also be considered when comparing these frac-
tions. For example, additional file 3 (Table A2) provides
spectral count information for the eight proteins identi-
fied by HPLC MS/MS, and indicates that some of these
were roughly similar in concentration, i.e., guanine nucle-
otide binding protein G (i) alpha-2 subunit, CD18, and
Beta-actin. In contrast, CD11b, matrix metalloproteinase-
9, lactoferrin, myeloperoxidase and serum albumin were
all significantly more abundant in the enriched secretory
vesicle fraction, even when accounting for total protein
loading differences (Figure 2). As previously reported, the
secretory vesicles also contained serum albumin [26],
although its presence in the enriched PMV fraction has
not been reported before and appears to be at considera-
bly lower concentrations.
In other cases, there were marked differences in classes of
proteins identified between the plasma membrane and
secretory vesicles. For example, several mitochondrial and
ER proteins (11), metabolic enzymes (3), NADPH oxi-
dases (1), and proteins involved in differentiation (2)
were identified by mass spectrometry only in the secretory
vesicle preparation. The presence of so many mitochon-
drial and ER proteins in the secretory vesicle preparation
was not unexpected in the light membranes from eukary-
otic cells, although mature PMN are terminally differenti-
ated and exhibit limited proteins synthesis under resting
condition [1]. Electron microscopy analysis of the two
vesicle preparations also identified mitochondria and ER
organelles in the SV fraction (data not shown).
In addition to the previously recognized proteins, several
novel proteins were identified that had not previously
been demonstrated to reside in secretory vesicles includ-
ing 5-lipoxygenase-activating protein (FLAP) and dysfer-
lin. Whereas FLAP had previously been recovered from
PMN [27], dysferlin had been identified by a proteomic
analysis to be located in the peroxidase-negative granules
of resting PMN [20]:  neither protein was previously
reported to be in PMV or SV.
In order to validate the novel identification of FLAP and
dysferlin using an independent analytical method, PMV
and SV were probed immunochemically for the presence
of FLAP (Figure 4B) and dysferlin (Figure 4C). Both mon-
omeric (18-kDa) and dimeric FLAP were detected immu-
nochemically in PMN membranes, with most of the FLAP
in the SV and relatively little present in the PMV (Figure
4B). Likewise, the presence of dysferlin in SV and PMV
from resting PMN was confirmed (Figure 4C). In addition
the identities of dysferlin (Figure 5A) and FLAP (Figure
5B) were confirmed by MS/MS spectra of specific tryptic
peptide fragments.
Secretogogue-induced redistribution of dysferlin
Given our demonstration that lights membranes from ER,
Golgi, and mitochondria were present in our PMV- and
SV-enriched fractions, we reasoned that our recovery of
dysferlin in the SV fraction could reflect the bona fide pres-
ence of dysferlin SV or a contribution from contaminating
light membranes that co-localized with SV after FFE. To
resolve between these two possibilities, we subjected light
membranes from resting and stimulated PMN to FFE to
determine if secretogogue treatment elicited a redistribu-
tion of dysferlin to PMV. PMN were stimulated with 10
μM formyl-methionyl-leucyl-phenylalanine (fMLF), a
well characterized PMN secretogogue, for 15 minutes at
37°C and PMV and SV were isolated and analyzed. As
demonstrated by the redistribution of latent alkaline
phosphatase activity, exposure to fMLF resulted in a disap-
pearance of SV, manifested as the loss of latent alkaline
phosphatase activity, and an increase in the non-latent
activity (Figures 6A and 6B), consistent with fusion of SV
with the PMV. Purified PMV and SV from resting or fMLF-
stimulated PMN were separated by SDS-PAGE, electrob-
lotted, and the resulting blots probed with anti-dysferlin
(Figure 6C). As a control for intracellular membrane
recruitment, samples were also probed with 54.1, as flav-
ocytochrome b558 expression at the PMN surface increases
with agonist-stimulated granule and secretory vesicle
fusion with PMV (Figure 6D) [13]. Dysferlin expression at
the cell surface increased after secretogogue treatment, just
as did flavocytochrome b558 expression. These data indi-
cate that, like flavocytochrome b558, dysferlin is recruited
from intracellular vesicles to fuse at the PMV and that the
dysferlin detected in resting PMN was in SV and not due
to contamination with other light membrane organelles.
Discussion
Agonist-dependent PMN stimulation during acute inflam-
mation, including activation of the NADPH oxidase and
release of granule contents, demonstrates the efficient and
speedy manner in which innate immunity up-regulates its
machinery in response to microbial threats [28]. Both
primed as well as fully activated PMN increase surface
expression of a wide variety of receptors and functionally
important molecules by recruitment from intracellular
stores [1], which include not only the specific and
azurophilic granules [4] but also membrane-bound secre-
tory vesicles [17]. In these studies we employed proteomic
analysis to survey the proteins present in plasma mem-
brane and in the extremely labile secretory vesicle pool to
better understand the complete repertoire of functional
remodeling that can accompany secretory vesicle fusion.Proteome Science 2007, 5:12 http://www.proteomesci.com/content/5/1/12
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Table 1: Classification of proteins identified from fractions enriched for plasma membrane and secretory vesicles.
Plasma membrane vesicles Secretory vesicles
Adhesion
Integrin alpha-M (CD11b)
Integrin beta-2 (CD18 antigen)
Integrin alpha-IIb
Intercellular adhesion molecule-3 (ICAM-3)
Phagocytic glycoprotein I (CD44 antigen)
Integrin alpha-M (CD11b)
Integrin beta-2 (CD18 antigen)
ADP-ribosyl cyclase 2 (CD157 antigen)
Erythrocyte band 7 integral membrane protein (Stomatin)
Cytoskeletal
Beta-actin (ACTB)
Alpha-actinin 1
Alpha-actinin 4
Cofilin, non-muscle form
Coronin-1A
Moesin
Myosin light polypeptide 6
Myosin regulatory light chain 2, nonsarcomeric
Tropomyosin alpha 3 chain
Tropomyosin beta chain
Beta-actin (ACTB)
Myosin-9
Tubulin alpha-ubiquitous chain
Signal transduction
Guanine nucleotide-binding protein G(i), alpha-2 subunit
Tyrosine protein kinase Lyn *
Flotillin*
B-cell receptor-associated protein 31
Chloride intracellular channel protein 1
Guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 1
HLA class I histocompatibility antigen, A-26 alpha chain
Interferon-induced transmembrane protein 1
Ras-related protein Rap-1A
Ras-related protein Rab-5A
Ras-related protein Rap-1b
Ras-related protein Rab-27B
Synaptosomal-associated protein 23
Guanine nucleotide-binding protein G(i), alpha-2 subunit
Tyrosine protein kinase Lyn *
Flotillin*
Adipocyte plasma membrane-associated protein
C5a anaphylatoxin chemotactic receptor
Dysferlin
Leukocyte surface antigen CD47
5-lipoxygenase activating protein (FLAP)
Solute carrier family 2, facilitated glucose transporter, member 3
NADPH oxidase
Cytochrome b-245 heavy chain (gp91phox)* Cytochrome b-245 heavy chain (gp91phox)
Differentiation
Myeloid-associated differentiation marker (SB135)
Leukocyte common antigen (CD45 antigen)Proteome Science 2007, 5:12 http://www.proteomesci.com/content/5/1/12
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Serum protein
Serum albumin Serum albumin
Alpha-1-antitrypsin
Ig gamma-1 chain C region
Mitochondrial/Microsomal
ATP synthase alpha chain, mitochondrial
ATP synthase beta chain, mitochondrial
Citrate synthase, mitochondrial
Cytochrome P450 4F2
60 kDa heat shock protein, mitochondrial (Hsp60)
Isocitrate dehydrogenase [NADP], mitochondrial
Malate dehydrogenase, mitochondrial
Sarcoplasmic/endoplasmic reticulum calcium ATPase 3
Sulfide: quinone oxidoreductase, mitochondrial
Trifunctional enzyme beta subunit, mitochondrial
Vacuolar ATP synthase subunit d
Metabolic
Aldehyde dehydrogenase 3B2
Dehydrogenase/reductase SDR family member 7
Tyrosine-protein phosphatase non-receptor type substrate 1
Granule
Lactoferrin
Matrix metalloproteinase 9
Myeloperoxidase
Cathepsin G
Azurocidin
Lactoferrin
Matrix metalloproteinase 9
Myeloperoxidase
Aminopeptidase N (CD13 antigen)
Eosinophil peroxidase
Cytosolic
14-3-3 protein zeta/delta Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit
Unknown
Actin-related protein 2
Golgi-associated plant pathogenesis related protein 1
Protein FAM49B
Tetratricopeptide repeat protein 10
ERO1-like protein alpha
Pantophysin
* Proteins identified only by immunoblotting are listed in italics. All other proteins identified by mass spectrometry.
Table 1: Classification of proteins identified from fractions enriched for plasma membrane and secretory vesicles. (Continued)Proteome Science 2007, 5:12 http://www.proteomesci.com/content/5/1/12
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Secretory vesicles are a relatively recently identified sub-
cellular compartment in PMN, separated by free-flow elec-
trophoresis of the light membrane fraction isolated from
discontinuous Percoll gradients [17,29]. Although a
method using sucrose flotation also has been employed to
recover SV [30,31] it has never been compared with FFE.
However, features of the fractions recovered by sucrose
flotation closely parallel those of the secretory vesicles iso-
lated by FFE, suggesting that the method may well recover
authentic SV. Whereas the lumen of the secretory vesicles
contains plasma proteins, its membranes possess flavocy-
tochrome b558,  β2 integrin CD11b/18, formyl peptide
receptor, CR1, CD16, and leukosylin [17,26,32-34].
Proinflammatory stimuli mobilize secretory vesicles and
trigger graded degranulation of the specific granules,
thereby integrating membrane proteins from these intrac-
ellular vesicles and granules into the PM. Consequently,
the resting PMN becomes transformed into a cell more
responsive to subsequent challenge by increasing the
number of effectors molecules available at the PMN sur-
face [14].
Of the 43 proteins recovered from secretory vesicles, a
minority had been identified previously in this neutrophil
compartment. The β2 integrins CD11b and CD18, CD13,
CD45, flavocytochrome b558, V-type H+ ATPase, and the
Rabs are functionally important proteins that were previ-
ously identified as constituents of membranes of secretory
vesicles [14,35]. For most proteins recovered however,
this report represents their first direct identification in
human PMN or in PMN secretory vesicles. Highly
expressed on myeloid cells throughout all stages of differ-
entiation [36], CD157 is detected on the surface of mature
PMN and increases after exposure to formyl peptides [37].
CD157 is a glycosylphosphatidyl inositol-anchored pro-
tein that has been implicated in inducing cytoskeletal
rearrangement important for shape changes integral for
PMN adhesion and movement [37]. Like many other
functionally important membrane proteins in PMN,
CD157 is thus compartmentalized in secretory vesicles as
an intracellular reservoir easily recruited during PMN acti-
vation. Proteins such as cofilin [38,39], CD13 [40], sto-
matin [41,42], Rab5 [43], and development- and
differentiation-enhancing factor 2 [44] have been impli-
cated in endosomal pathway recycling or other events in
phagosome maturation [45] in a variety of cell types.
Proteomic analysis is extremely sensitive, demonstrated in
our studies by the detection of two classes of contami-
nants in our PMV- and SV-enriched fractions. We identi-
fied resident proteins specific for ER, Golgi, and
mitochondria; although the presence of so many mito-
chondrial and ER proteins is not unexpected in the light
membranes from eukaryotic cells, many human PMN are
terminally differentiated and exhibit very limited protein
synthesis under resting conditions [1] making such pro-
teins at extremely low abundance. As we noted, our anal-
ysis also included the identification of granule-associated
proteins in fractions that are free of granules. Granules are
partially disrupted during the N2 cavitation, as observed in
the original report of the method (reference [13]) and on
several occasions since that publication [46,47]. In a
recent report of proteomic analysis of the granules from
human PMN [20], the authors documented the release of
soluble granule proteins during sample preparation with
resultant cross contamination of the three granule popu-
lations subsequently analyzed. Most (75%) of the gelati-
nase was recovered in the gelatinase-positive granules, but
20% and 5% of the total contaminated specific and
azurophilic granules, respectively. By the same token,
most (73%) of the myeloperoxidase was recovered in
MPO-containing azurophilic granules, but 20% and 7%
of the total contaminated specific and gelatinase-positive
granules, respectively. Thus, soluble granule proteins are
released to a limited degree during sample preparation
and can contaminate other fractions. We believe that this
phenomenon explains our detection of granule proteins
in granule-free fractions. It is likely that the soluble pro-
teins released from the granules associate with vesicular
membranes and thereby co-sediment in the particular
membrane fraction in which they were recovered. Con-
Immunochemical analysis of specific proteins in PMV- and SV- enriched fractions Figure 4
Immunochemical analysis of specific proteins in 
PMV- and SV-enriched fractions. Plasma membrane ves-
icles (PMV) and secretory vesicles (SV) fractions were sepa-
rated by SDS-PAGE, electroblotted and probed with 
antibodies against several proteins: (A) Lyn and Flotillin, (B) 
FLAP, and (C) Dysferlin. The lower molecular weight band 
visualized in panel C of both lanes does not correspond to 
the expected size for dysferlin and may be the result of lim-
ited proteolysis of dysferlin during organelle isolation or a 
non-specific immunoreactive protein unrelated to dysferlin.
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sistent with this interpretation, most of the PMN granule
proteins, including myeloperoxidase, azurocidin, lactofer-
rin, and cathepsin G, as well as the eosinophil-derived
eosinophil peroxidase, are present in millimolar concen-
trations, are extremely cationic, and avidly associate with
membranes. Furthermore, PMV and SV-enriched fractions
also contained actin and actin-associated proteins, which
very likely reflect cytoskeletal contamination of the frac-
tions. The challenges posed by the overabundance of cat-
ionic granule proteins and cytoskeletal elements to
obtaining pure preparations of subcellular membrane-
bound compartments can be decreased, in part, by wash-
ing membranes with carbonate buffers at pH 11, as done
recently in a proteomic analysis of granule membrane
proteins [24]. Because of concern for the relative lability
of PMV and SV in contrast to granules, we elected to study
the recovered fractions without washing with relatively
harsh conditions. Consequently, PMV- and SV-enriched
fractions in our studies were contaminated with soluble
granule proteins.
Our identifications of FLAP and dysferlin in SV and PMV
of resting PMN represent novel findings. First identified
over a decade ago [27], FLAP is an 18-kDa membrane pro-
tein that is essential for 5-lipoxygenase activity and there-
fore for the biosynthesis of leukotrienes [48]. Inhibition
of FLAP translocation blocks leukotriene production by
stimulated cells, thus intimately linked FLAP redistribu-
tion with 5-lipoxygenase activity [49,50]. FLAP is required
for the calcium-dependent translocation of 5-lipoxygen-
ase from cytosol to nuclear membrane, a prerequisite for
Secretogogue-induced redistribution of dysferlin Figure 6
Secretogogue-induced redistribution of dysferlin. (A) 
Isolated resting PMN were disrupted by N2 cavitation and 
fractionated using a two-step discontinuous gradient of Per-
coll. The γ band containing the light membranes was recov-
ered, treated with neuraminidase, and subjected to free-flow 
electrophoresis to resolve plasma membranes vesicles from 
secretory vesicles. Fractions (96) were collected and assayed 
spectrophotometrically for alkaline phosphatase activity in 
the absence (❍) and presence () of Triton X-100. (B) The 
PMN were isolated as above and were exposed to fMLF 
(formyl methionyl-leucyl-phenylalanine). Fractions (96) were 
collected and assayed spectrophotometrically for alkaline 
phosphatase activity in the absence of (❍) and presence () 
of Triton X-100 after exposure to fMLF. The exposure to 
fMLF resulted in a loss of SV (i.e. loss of latent alkaline phos-
phatase activity), consistent with their fusion with the plasma 
membrane. (C) Purified PMV and SV from resting or fMLF-
stimulated PMN were separated by SDS-PAGE, electroblot-
ted, and the resulting blots probed with anti-dysferlin. (D) As 
a control for intracellular membrane recruitment, samples 
were also probed with 54.1, as flavocytochrome b558 expres-
sion at the PMN surface increases with agonist-stimulated 
granule and secretory vesicle fusion with plasma membrane.
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Tandem mass spectra for FLAP and dysferlin Figure 5
Tandem mass spectra for FLAP and dysferlin. (A) The 
MS/MS spectrum of dysferlin peptide "IGETVVDLENR" of m/
z 623.5 (Molecular mass of 1245.4 Da) after free flow elec-
trophoresis, tryptic digestion and 1D gel (spot 9 in Figure 2, 
SV) of the secretory vesicles and (B) The MS/MS spectrum 
of FLAP peptide "YFVGYLGER" of m/z 552.3 (molecular 
mass of 1104.2 Da) after free flow electrophoresis, tryptic 
digest and ID gel (Spot 1 on Fig 2, SV) of the secretory vesi-
cles.
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5-lipoxygenase activity [51,52]. Immunoelectron micros-
copy of ultra-thin frozen sections of resting and stimu-
lated PMN demonstrates localization of FLAP exclusively
on the nuclear membrane; no other cellular compart-
ments, including plasma membrane were immunoreac-
tive [46]. The previous failure to detect FLAP at plasma
membrane or in secretory vesicles could reflect technical
limitations of the anti-peptide antibody used, as sug-
gested by the authors [53], as it was raised to an 11 amino
acid linear region in FLAP [50]. More recently both mon-
omeric and dimeric FLAP were identified in the light
membranes recovered from the post-nuclear supernatant
of sonicated human PMN [54]. It is possible that the N2
cavitation used to disrupt PMN to generate membrane
vesicles may have inadvertently resulted in contamination
of the starting material with nuclear membranes. How-
ever this explanation appears less likely, as the low speed
centrifugation of the cavitate that precedes loading the
Percoll gradient removes ~85% of the DNA [13] and we
recovered no other nuclear protein in our proteomic anal-
ysis (Table 1). However, additional studies directly exam-
ining the subcellular location of FLAP in resting PMN are
needed to resolve this issue.
Notable among the novel proteins identified by HPLC-
MS/MS in secretory vesicles is LGMD2B, the membrane
protein encoded by the gene that is mutated in two
human muscular dystrophies, limb-girdle muscular dys-
trophy type 2B (LGMD2B) [55,56] and Miyoshi myopa-
thy (MM) [57]. Dysferlin is a member of the newly
described ferlin protein family that also includes myofer-
lin and otoferlin. These proteins share homology with fer-
1, a spermatogenesis factor in C. elegans [reviewed in
[58]]. Mutations in fer-1 compromise vesicle fusion with
the plasma membrane, whereas dysferlin functions in the
normal repair of the plasma membrane of skeletal muscle
[59], observations that suggest that the dysferlin may par-
ticipate in fusion events at the plasma membrane. Our
data demonstrate agonist-dependent redistribution of
dysferlin from SV to PMV but do not address how dysfer-
lin might directly contribute to this up-regulation. It is not
known if dysferlin mediates directly or cooperates with
other proteins to facilitate membrane fusion. It is possible
that in PMN dysferlin mediates the fusion of secretory ves-
icles with plasma membrane during PMN priming in
response to proinflammatory stimuli or as part of mem-
brane remodeling that accompanies PMN activation, as
seen during adhesion, endothelial transmigration, chem-
otaxis, and phagocytosis. The involvement of dysferlin in
PMN-mediated immune response is supported both by
the exuberant inflammatory infiltrate observed in the
muscles of patients with LGMD2B and MM, and by histo-
logical changes seen in dysferlin knock-out mice. Further-
more, recent reports have noted that PMN depletion has a
protective effect in muscular dystrophies. Further charac-
terization of the activity of dysferlin in secretory vesicles
may provide important and novel insights into PMN cell
biology.
Conclusion
Our data demonstrate that the broad array of proteins
present in secretory vesicles that provides the PMN with
the capacity for remarkable and rapid reorganization of its
plasma membrane after exposure to proinflammatory
agents or stimuli. The increased surface expression of
membrane proteins from secretory vesicles coupled with
the amplification of various intracellular signaling path-
ways allow the PMN to rapidly change from a resting state
to an activated phenotype better primed for antimicrobial
action. Ongoing studies to extend the known repertoire of
proteins present in secretory vesicles and their functional
consequences may reveal novel insights into the mecha-
nisms of PMN activation during acute inflammation.
Methods
Reagents and antibodies
The protease inhibitors [phenylmethylsulfonyl fluoride
(PMSF), aprotinin, phosphoramidone, n-tosyl-lysyl-chlo-
romethyl ketone (TLCK), n-tosyl-phenyl-chloromethyl
ketone (TPCK), amidinophenylmethylsulfonylfluoride
(APMSF), E-64, leupeptin, and pepstatin, diisopro-
pylfluorophosphate (DFP)], neuraminidase type X from
Clostridium perfringens, and p-nitrophenyl phosphate, 2-
amino-2-methyl-1-propanol were purchased from Sigma
Chemical Co. (St. Louis, MO). Density gradient centrifu-
gation media, Percoll, and Hypaque-Ficoll were pur-
chased from Amersham Biosciences (Uppsala, Sweden).
Sodium dodecyl sulphate (SDS) was purchased from
Research Products International Corp. (Mt. Prospect, IL);
acrylamide was obtained from Bio-Rad laboratories (Her-
cules, CA); Hanks' balanced salt solution (HBSS) was pur-
chased from Bio Whittaker (Walkersville, Maryland). BCA
Protein Assay Kit and ECL Western Blotting Detection
Reagents were obtained from Pierce (Rockford, IL). Endo-
toxin-free saline and H2O were purchased from Baxter
Healthcare Corporation (Deerfield, IL).
Materials related to proteomics, such as sample buffers
and 1D 4–20% PAGE gels were obtained from Bio-Rad
Laboratories (Hercules, CA). Gel stain SYPRO ruby was
obtained from Molecular Probes/Invitrogen (Carlsbad,
CA). For proteolysis, sequencing grade, modified porcine
trypsin was purchased from Promega (Madison, WI).
Additional reagents for analytical protein chemistry
including iodoacetamide and dithiothreitol were
obtained from Sigma (St. Louis, MO). HPLC solvents such
as acetonitrile and water were obtained from Burdick &
Jackson (Muskegon, MI). For MALDI-MS experiments a
matrix solution of α-cyano-4-hydroxycinnamic acid inProteome Science 2007, 5:12 http://www.proteomesci.com/content/5/1/12
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acetonitrile/methanol was purchased from Agilent Tech-
nologies (Palo Alto, CA).
Antibody against lyn was obtained from Santa Cruz Bio-
technology (Santa Cruz, CA). Antibody against flotillin-1
was purchased from BD Transduction Laboratories (BD
Sciences, San Jose, CA). Antibody against dysferlin, NCL-
Hamlet, was purchased from Novocastra (Newcastle
upon Tyne, UK). Secondary antibodies used: horseradish
peroxidase (HRP)-conjugated goat anti-mouse was pur-
chased from Bio-Rad Laboratories (Hercules, CA); HRP-
conjugated rabbit anti-goat IgG was purchased from ICN
Biochemicals, Inc. (Aurora, OH); and HRP-conjugated
donkey anti-rabbit IgG was purchased from Amersham
Biochemicals UK limited. Immunoblotting for 5-lipoxy-
genase activating protein was kindly performed by Dr.
Roy J. Soberman (Harvard University, Boston, MA).
All reagents and materials used in the preparation of PMN
(i.e. HBSS, Hypaque-Ficoll, Dextran/NaCl, H2O, and
saline solutions) were free of endotoxin at <10 pg/ml, as
determined by Limulus  amebocyte lysate assay (QCL-
1000, Bio Whittaker, Inc., Walkersville, MD).
Neutrophil isolation
Heparinized, venous blood was obtained from healthy
individuals after informed consent and in accordance
with a protocol approved by the Institutional Review
Board for the University of Iowa. Human PMN were iso-
lated by dextran sedimentation followed by Hypaque-
Ficoll differential density gradient centrifugation and
hypotonic lysis of erythrocytes as described previously
[15]. Purified PMN ≥ 95% of the cells of the preparation
were resuspended in calcium-free HBSS and kept on ice
until use.
Isolation of PMN plasma membranes
PMN were disrupted by N2 cavitation and plasma mem-
brane-rich fractions were isolated by centrifugation of the
postnuclear supernatant on a density gradient of Percoll,
as previously described [13]. Briefly, PMN were treated
with 1 mM DFP at 4°C for 20 min to inactivate serine este-
rases, washed, and resuspended at 1.5–2.0 × 108 PMN/ml
in 3 ml of relaxation buffer (RB) (10 mM PIPES, 100 mM
KCl, 3 mM NaCl, 3.5 mM MgCl2, 1 mM ATP, 1.25 mM
EGTA, pH 7.3) containing a mix of protease inhibitors
(0.5 mM PMSF, 1 μM aprotinin, 1 μM phosphoramidone,
1 μM TLCK, 2 μM TPCK, 1 μM APMSF, 1 μM E-64, 0.5 μM
leupeptin, 0. 1 μM pepstatin), and disrupted by N2 cavita-
tion (350 psi). All manipulations were carried out at 0–
4°C. The cavitate was centrifuged at 200 × g for 10 min to
remove nuclei and unbroken cells, and 2–3 ml of post
nuclear supernatant were loaded onto a 2 step Percoll gra-
dient in RB [13]. Density gradients were generated by cen-
trifugation at 48,400× g  for 20 min in a JA-20 rotor
(Beckman). After centrifugation at 140,000 × g for 1 h to
remove residual Percoll, the γ fraction, which contains
plasma membranes and secretory vesicles, was resus-
pended in RB containing protease inhibitors, flash frozen
in a dry ice-methanol bath, and stored at -80°C.
Free flow electrophoresis
In order to separate plasma membrane vesicles from
secretory vesicles in the γ fraction isolated from the Percoll
gradient of capitates PMN, free flow electrophoresis was
performed, according to previously published methods
[17,60]. To reduce the surface charge of plasma mem-
brane vesicles, the γ fraction was treated with neuramini-
dase type X from Clostridium perfringens (0.02 units/ml)
for 30 min at 37°C and recovered by ultra centrifugation
(120,000 × g for 45 min). The pellet was resuspended in
chamber buffer (5 mM triethanolamine, 5 mM acetic acid,
270 mM sucrose, pH 7.4, conductivity: 0.42 mohm-1) by
15 aspirations through a 21-gauge syringe and adjusted to
a protein concentration of approximately 1 mg/ml. Elec-
trode buffer was 50 mM triethanolamine and 50 mM ace-
tic acid, pH 7.4 and the chamber buffer was degassed
before electrophoresis. Free flow electrophoresis was per-
formed using an Elphor HV 600 (Bender & Hobein,
Munich, Germany) at 5°C, a sample inlet of 3.0 ml/h, a
chamber buffer flow rate of 3.2 ml/h/fraction, and the cur-
rent set to 100 mA giving a voltage of 1000 V ± 5%, as pre-
viously described [17,60]. Fractions (96) were collected
and assayed for the presence of alkaline phosphatase
activity, using a previously described method. Briefly, 100
μl of each fraction was added to separate wells of a 96-well
flat-bottom plate and then mixed with 200 μl of reaction
buffer (5 mM p-nitrophenyl phosphate in 100 mM 2-
amino-2-methyl-1-propanol, pH 10.0). Reaction mix-
tures were incubated (15 min, 37°C), and the absorbance
was then read in a microplate reader at 405 nm. Based on
the profile of non-latent alkaline phosphatase activity rep-
resenting plasma membrane (determined in the absence
of Triton X-100) and latent alkaline phosphatase activity
representing secretory vesicles (determined in the pres-
ence of Triton X-100), selected fractions were pooled and
the membranes recovered by centrifugation (100,000 × g
for 20 h at 4°C in a Beckman SW 32Ti rotor). The mem-
brane pellet was collected and resuspended in RB. To
remove residual sucrose, the suspension was centrifuged
for 30 min at 100,000 × g at 4°C in a Beckman TLA 120.2
rotor. The membrane pellet was resuspended in RB, flash
frozen, and stored at 4°C until further use.
Gel electrophoresis and immunoblotting
Fractions of plasma membrane and secretory vesicles sep-
arated by free flow electrophoresis were solubilized in
SDS-sample buffer (62 mM Tris-HCl, pH 6.8, 2.3 % SDS,
5 % BME (v/v), 5 % glycerol), boiled for 5 min at 100°C
and were run on 4–20% SDS PAGE mini ready gels (Bio-Proteome Science 2007, 5:12 http://www.proteomesci.com/content/5/1/12
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Rad, Hercules, CA) and stained with Sypro Ruby (Molec-
ular Probes, Eugene, OR) according to manufacturer's
instructions. The gels were scanned on Typhoon 8610 var-
iable model imager and densitometer analysis were done
by ImageQuant5.2 (Molecular Dynamics, part of Amer-
sham Pharmacia Biotech, Piscataway, NJ). For studies of
dysferlin, 3–15% gradients gels were used for SDS-PAGE.
For immunoblotting, gels were electro transferred to
nitrocellulose membranes (Schleicher & Schuell, Florham
Park, NJ) at room temperature at constant voltage of 50
volts for 3 hr and blots were processed using the ECL kit
according to the manufacturer's instructions.
In-gel tryptic digestion of proteins
The protein bandsvisualized by SYPRO Ruby staining
were labeled from top to bottom ineach lane (see Figure
2), excised using a 1.5 mm gel picker (# P2D1.5, The Gel
Company, San Francisco, CA) and processed with an
automatic in-gel digester robot, ProGest (Genomic Solu-
tions, Ann Arbor, MI). Processing steps consisted of
destaining and dehydrating the excised gel slices with ace-
tonitrile, reduction with 10 mM DTT at 60°C for 30 min,
alkylation of cysteine residues with 100 mM iodoaceta-
mide (37°C, 45 min), and proteolytic digestion using
125–250 ng sequencing grade trypsin (Promega, Madi-
son, WI) at 37°C for 4 h. The resulting tryptic peptides
were then extracted from the gel by aqueous/10% formic
acid extraction and analyzed by mass spectrometry [61].
Mass spectrometry
Mass spectra of digested gel spots were obtained by
matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) mass spectrometry on a Voyager DESTR
plus instrument (Applied Biosystems, Framingham, MA).
All mass spectra were acquired in positive-ionization
mode with reflectron optics. The instrument was
equipped with a 337 nm nitrogen laser and operated
under delayed extraction conditions; delay time 190 nsec,
grid voltage 66–70% of full acceleration voltage (20–25
kV). All peptide samples were prepared using a matrix
solution consisting of 33 mM α-cyano-4-hydroxycin-
namic acid in acetonitrile/methanol (1/1; v/v); 1 μl of
analyte (0.1–1 pmol of material) was mixed with 1 μl of
matrix solution, and then air-dried at room temperature
on a stainless steel target. Typically, 50–100 laser shots
were used to record each spectrum. The obtained mass
spectra were externally calibrated with an equimolar mix-
ture of angiotensin I, ACTH 1–17, ACTH 18–39, and
ACTH 7–38.
All proteolytic peptide extracts were analyzed by HPLC
MS/MS using an Agilent Nanoflow Proteomics system
that consisted of a nanoflow liquid chromatograph (LC)
system coupled to an Agilent 1100 Series XCT ion trap
mass spectrometer with an on-line orthogonal nanoelec-
trospray source. For LC separations, samples (~8 μl) were
injected and then enriched and de-salted on a trap col-
umn (Zorbax 300SBC18, 150 mm × 75 μm, 3.5 μm)
before being transferred and separated on a Zorbax
300SB-C18 nanocapillary column (5 mm × 300 μm, 5
μm) with a flow rate of 300 nl/min. The LC gradient con-
sisted of 3% B at 0 min, 3% B at 5 min, 15% at 8 min, 45%
at 50 min, 90% at 55 min, 90% at 60 min, 3% at 61 min
and a stop time of 75 min. Solvents were: A = 0.1% formic
acid in water, B = 0.1% formic acid in acetonitrile In all
cases, peptide samples were analyzed in the positive ion
mode under the following hardware and software condi-
tions: Vcap: typically 1800–2000 V; Drying gas flow: 5 L/
min; Drying gas temperature: 300°C; Skim 1: 30 V; Capil-
lary exit offset: 75 V; Trap Drive: 85; Averages: 2; ICC: On;
Maximum accumulation time: 150 ms; Smart Target:
125,000; MS Scan range: 300–2200; Automatic MS/MS:
Peptide Scan mode (standard-enhanced for MS and Ultra
Scan for MS/MS); Number of parents: 3; Averages: 2; Frag-
mentation amplitude: 1.3 V; SmartFrag: On, 30–200%;
Active Exclusion: On, 2 spectra, 1 min; Prefer +2: on; MS/
MS Scan Range: 50–2200 m/z.
Database searches
Mass spectrometric data were analyzed with two in-house
licensed bioinformatics database search engine systems,
RADARS (Genomic Solutions, Ann Arbor, MI) [62] and
Mascot Wizard (Matrix Sciences, London, United King-
dom) [63] MALDI-MS data were analyzed with RADARS
and Mascot Wizard using the search engine ProFound and
Mascot bioinformatics database search engine for Peptide
Mass Fingerprint (PMF) matching against peptides from
known protein sequences entered in publicly available
SwissProt protein databases using the following parame-
ters: internal calibration using trypsin autolysis masses
(m/z 842.5100 and 2211.1046), 100 ppm mass accuracy,
2 missed proteolytic cleavages allowed. Profound uses an
'expectation value' for data quality control that gets
smaller as the probability of a nonrandom (real) protein
hit increases, e.g. 1 × 10-2 is a 1 in 100 chance of being a
random hit (confidence > 99.0%), 1 × 10-3 is a 1 in 1000
chance of being a random hit (confidence > 99.9%); pro-
tein matches are considered significant for scores with
expectation value <5 × 10-2 (confidence >95%)[62]. Mas-
cot Wizard score was -10*Log(P), where P is the probabil-
ity that the observed match was a random event. Protein
scores greater than 64 are significant (p < 0.05). For Ion-
Trap-MS/MS data sets spectra were submitted to Mascot
searching against the publicly available SwissProt data-
base for Homo sapiens. Mascot uses a probability based
'Mowse Score' to evaluate data obtained from tandem
mass spectra, e.g. for a score > 42, protein matches are
considered significant [63]. For LC-MS/MS acquired data
a minimum of two observed peptides that were selected
for tandem mass spectrometry was required to confirmProteome Science 2007, 5:12 http://www.proteomesci.com/content/5/1/12
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protein identification; in the few cases where only one
unique peptide per protein was selected for MS/MS, the
MS/MS spectrum inspected "manually" based on previ-
ously published criteria and thus confirmed or deleted
from the identification list [64]. These latter proteins are
listed in italics in table A1 (Additional file 2). All "single
hit" proteins listed in table A1 (additional file 2) were
additionally validated by comparing MS/MS spectra to
those in the global proteome machine (GPM). Details of
these methods and inclusion criteria are described more
fully in the table A1 (additional file 2) legend section.
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